|
|
|
|
LEADER |
00000cam a2200000Ii 4500 |
001 |
SCIDIR_on1329314428 |
003 |
OCoLC |
005 |
20231120010649.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
220613s2022 ne o 000 0 eng d |
040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d OCLCF
|d SFB
|d OCLCQ
|
020 |
|
|
|z 9780323988490
|
020 |
|
|
|z 0323988490
|
035 |
|
|
|a (OCoLC)1329314428
|
050 |
|
4 |
|a RB40
|
082 |
0 |
4 |
|a 616.0756
|2 23
|
245 |
0 |
0 |
|a Advances in clinical chemistry.
|n Volume 108 /
|c edited by Gregory S. Makowski.
|
264 |
|
1 |
|a Amsterdam :
|b Academic Press,
|c 2022.
|
300 |
|
|
|a 1 online resource (1 volume)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
520 |
|
|
|a Advances in Clinical Chemistry, Volume 108, the latest installment in this internationally acclaimed series, contains chapters authored by world-renowned clinical laboratory scientists, physicians and research scientists. The serial discusses the latest and most up-to-date technologies related to the field of clinical chemistry, with this new release focusing on Nephrinuria and podocytopathies, Extracellular vesicles in respiratory disease, Diabetes and cognitive decline, Testosterone analysis in prostate cancer, Mono/polyclonal free light chains as challenging biomarkers for immunological abnormalities, and more.
|
588 |
0 |
|
|a Print version record.
|
505 |
8 |
|
|a Chapter Three: Testosterone analysis in prostate cancer patients -- 1. Introduction -- 2. Gonadal testosterone regulation -- 3. Evolution of androgen deprivation therapy -- 3.1. Surgical intervention and estrogen administration -- 3.2. LHRH agonists and antagonists -- 3.3. AR inhibitors -- 3.4. CYP17A1 inhibition -- 3.5. Bipolar androgen therapy -- 4. Testosterone analysis -- 4.1. Early testosterone analysis -- 4.2. Contemporary testosterone analysis -- 4.2.1. Automated IA -- 4.2.2. Mass spectrometry-based assays -- 5. Automated IA vs LC-MS/MS assays -- 6. Potential clinical utility of ultra-sensitive testosterone assays -- 7. Conclusion -- References -- Chapter Four: Extracellular vesicles in respiratory disease -- 1. Introduction -- 1.1. Extracellular vesicles -- 1.2. Types of EVs -- 1.3. General functions of EVs -- 2. Experimental techniques for EV research -- 2.1. Methods for EV isolation -- 2.1.1. Differential centrifugation -- 2.1.2. Density gradient centrifugation -- 2.1.3. Size exclusion chromatography -- 2.1.4. Commercial kits for polymer precipitation -- 2.1.5. Precipitation with chemicals -- 2.1.6. Immunoprecipitation -- 2.1.7. Ultrafiltration -- 2.1.8. Microfluidic technologies -- 2.2. Methods for EV characterization -- 2.2.1. Dynamic light scattering -- 2.2.2. Nanoparticle tracking analysis -- 2.2.3. Nanoscale flow cytometry -- 2.2.4. Transmission electron microscopy -- 3. EVs in the respiratory system -- 3.1. EVs from BALF -- 3.2. Biological significance of EVs in common respiratory diseases -- 3.2.1. Acute lung injury and acute respiratory distress syndrome -- 3.2.2. Chronic obstructive pulmonary disease -- 3.2.3. Pulmonary arterial hypertension -- 3.2.4. Idiopathic pulmonary fibrosis -- 3.2.5. Asthma -- 3.3. Clinical applications of respiratory EVs -- 3.3.1. Respiratory EV-miRNAs as diagnostic markers.
|
650 |
|
0 |
|a Clinical chemistry.
|
650 |
|
7 |
|a Clinical chemistry.
|2 fast
|0 (OCoLC)fst00864330
|
700 |
1 |
|
|a Makowski, Gregory S.
|q (Gregory Stephen),
|e editor.
|1 https://isni.org/isni/0000000107166351
|
776 |
0 |
8 |
|i Print version:
|t Advances in clinical chemistry. 108.
|d Amsterdam : Academic Press, 2022
|z 9780323988490
|w (OCoLC)1314336241
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00652423/108
|z Texto completo
|